REFERENCES:

- [1] Colafrancesco S, Vomero M, Iannizzotto V, et al. Autophagy occurs in lymphocytes infiltrating Sjögren's syndrome minor salivary glands and correlates with histological severity of salivary gland lesions. *Arthritis research & therapy* 2020;22(1):238. doi: 10.1186/s13075-020-02317-6 [published Online First: 2020/10/15].
- [2] Alessandri C, Ciccio F, Priori R, et al. CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sjögren's syndrome patients and correlates with focus score and disease activity. *Arthritis research & therapy* 2017;19(1):178. doi: 10.1186/s13075-017-1385-y [published Online First: 2017/07/27].
- [3] Wei J, Long L, Yang K, et al. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis. *Nature immunology* 2016;17(3):277-85. doi: 10.1038/ni.3365 [published Online First: 2016/01/26].

Figure 1: (A) Identification of training dataset using NMF consensus clustering in the autophagy set. (B) Boxplot visualizing the autophagy score between two subtypes. (C) Boxplot visualizing the autophagy score between two subtypes. (D) Identification subtypes using NMF consensus clustering in the autophagy set in GSE51092. (E) Boxplot visualizing the autophagy score between two subtypes remained statistically significant. (F) NMF clustering using 206 ferroptosis-related genes. Salivary gland tissues from pSS patients were divided into cluster 1 and cluster 2. (G) The early group showed a higher autophagy score than the advanced group. (H) Boxplot visualizing the autophagy score between two subtypes remained statistically significant. (I) Boxplot visualizing the autophagy score between two subtypes remained statistically significant. (J) Boxplot visualizing the autophagy score between two subtypes remained statistically significant. ***P<0.001, **P<0.01, *P<0.05, ns P>0.05.

Acknowledgements: This project was supported by National Science Foundation of China (82001740), Open Fund from the Key Laboratory of Cellular Physiology (Shanxi Medical University) (KLCP2019) and Innovation Plan for Postgraduate Education in Shanxi Province (2020BY078).

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1769

POS0733

REAL-LIFE PHYSICAL ACTIVITY IN SLE PATIENTS: ASSOCIATIONS WITH FATIGUE AND QUALITY OF SLEEP

H. Wohland¹, N. Leuchten¹, M. Aringer¹. ¹University Medical Center and Faculty of Medicine TU Dresden, Department of Medicine III, Division of Rheumatology, Dresden, Germany

Background: Fatigue is among the top complaints of patients with systemic lupus erythematosus (SLE), but only in part associated with SLE disease activity. Physical activity can help to reduce fatigue and should therefore be recommended to SLE patients. Vice versa, fatigue may arguably lead to reduced physical activity.

Objectives: To investigate the extent of physical activity and the perception of fatigue and sleep quality in patients with SLE.

Methods: Starting in February 2019, SLE patients were invited to participate in a cross-sectional survey study of fatigue and physical exercise during their routine outpatient clinic visits. Participants filled out a ten-page paper questionnaire focused on physical activity. To evaluate fatigue, we primarily used a 10 cm visual analogue scale (0-100 mm, with 100 meaning most fatigued), but also the FACIT fatigue score (range 0-52). Sleep quality was estimated using grades from 1 (excellent) to 6 (extremely poor).

Results: 93 SLE patients took part in the study. All patients fulfilled the European League Against Rheumatism/ American College of Rheumatology (EULAR/ACR) 2019 classification criteria for SLE. 91% of the patients were female. Their mean (SD) age was 45.5 (14.3) years and their mean disease duration 12.1 (9.4) years. The mean BMI was 25.2 (5.6). Of all patients, 7.5% had a diagnosis of (secondary) fibromyalgia. The mean fatigue VAS was 32 (27) mm and the mean FACIT fatigue score 35.7 (10.3). As expected, fatigue by VAS and FACIT was correlated (Spearman $r=-0.61$, $p<0.0001$). The mean SLEDAI was 1 (1) with a

range of 0 to 6. Median glucocorticoid doses were 2 mg prednisolone equivalent, with a range from 0 to 10 mg.

Out of 66 patients in paid jobs, 64 (97%) reported details on their working space. One person (2%) worked in a predominantly standing position, 37 (58%) worked in essentially sedentary jobs and 26 (40%) were in positions where they were mildly physically active in part. The mean fatigue VAS was 31 (24) mm for patients with partly active jobs and 27 (30) mm for those in sedentary jobs. Sleep was graded 2.9 (0.9) by those with active and 3.1 (1.3) by those with sedentary jobs.

Half of the patients (51%) reported more than one physical recreational activity. 44 (47%) were walking and for five persons (5%) this was the only form of activity. Cycling was reported by 19 patients (20%), 18 of whom also practiced other activities. For transport, 52 (56%) in part chose active modes, such as walking and cycling. Patients who reported any of the above activities showed a mean fatigue VAS of 28 (25) mm, compared to 36 (28) mm in the patient group without a reported activity. Sleep quality was very similar: 3.1 (1.2) and 3.2 (1.1) for more active and more passive patients, respectively.

65 (70%) patients regularly practiced sports. Of these, 39 (60%) practiced one kind of sport, 15 (23%) two, 7 (11%) three, and 2 (3%) each four and five kinds of sports. Fatigue VAS of patients practicing sports was 27 (25) mm versus 43 (28) in those who did not ($p=0.0075$). Sleep quality was 2.9 (1.1) in the sports cohort and 3.5 (1.1) in the no-sports cohort ($p=0.0244$).

Conclusion: A majority of SLE patients in remission or low to moderate disease activity regularly practiced sports, and those doing so reported lesser fatigue and better sleep quality. The absolute values on the fatigue VAS were in a moderate range that made fatigue as the main cause of not performing sports rather unlikely for most patients.

Disclosure of Interests: Helena Wohland: None declared, Nicolai Leuchten Speakers bureau: AbbVie, Janssen, Novartis, Roche, UCB, Consultant of: AbbVie, Janssen, Novartis, Roche, Martin Aringer Speakers bureau: AbbVie, Astra Zeneca, BMS, Boehringer Ingelheim, Chugai, Gilead, GSK, HEXAL, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, Consultant of: AbbVie, Astra Zeneca, BMS, Boehringer Ingelheim, GSK, Lilly, MSD, Roche, Sanofi, UCB

DOI: 10.1136/annrheumdis-2021-eular.1775

POS0734

EXTRAPOLATION OF LONG-TERM OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS: REPLICATING A HOPKINS LUPUS COHORT ANALYSIS WITH THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT

A. E. Clarke¹, Y. St-Pierre², V. Paly³, I. N. Bruce⁴, C. Malmberg⁵, A. Briggs⁶, Y. Zhang⁷, J. Choi⁷, A. Brennan⁸ on behalf of Systemic Lupus International Collaborating Clinics. ¹University of Calgary, Division of Rheumatology, Calgary, Canada; ²McGill University Health Centre, Research Institute, Montreal, Canada; ³ICON plc, Global Health Economics and Outcomes Research (GHEOR), New York, United States of America; ⁴University of Manchester, The Kellgren Centre for Rheumatology, Manchester, United Kingdom; ⁵ICON plc, Global Health Economics and Outcomes Research (GHEOR), Stockholm, Sweden; ⁶London School of Hygiene & Tropical Medicine, Department of Health Services Research and Policy, London, United Kingdom; ⁷Bristol Myers Squibb, Worldwide HEOR, Lawrenceville, United States of America; ⁸University of Sheffield, Health Economics and Decision Science, School of Health and Related Research, Sheffield, United Kingdom

Background: A disease model of systemic lupus erythematosus (SLE) that predicts short-term outcomes (disease activity and prednisone use) and links them to long-term outcomes (accrual of organ damage and mortality) was previously developed in a single center SLE cohort (Johns Hopkins [JH]) to support health economic analyses (Watson 2015), which has not been comprehensively replicated in other cohorts or contexts.

Objectives: As part of an effort to develop and refine this existing disease model, the aim of this study was to replicate the previously estimated network of risk equations for short- and long-term outcomes in the SLICC Inception Cohort, an international cohort of patients (33 centers, 11 countries).

Methods: The SLICC Inception Cohort enrolled patients fulfilling ACR Classification Criteria for SLE within 15 months of diagnosis from 1999-2011 with annual follow-up through April 2020. The network of risk equations included two linear random effects models to predict (1) change in annual average Systemic Lupus Disease Activity Index (SLEDAI) score based on patient characteristics and the presence of renal, hematological, and immunological involvement in the prior year and (2) average annual prednisone dose based on SLEDAI score in the same year. These equations were then linked to parametric survival models that predicted time to the occurrence of organ damage (system-specific based on the ACR/SLICC Damage Index) and mortality. We compared model performance between the SLICC Cohort and the original analysis from the JH Cohort.

Results: In comparison to the JH cohort (N=1354), the SLICC cohort (N=1697) had a smaller fraction of patients of African descent (39% vs 17%) and shorter